| 000 | 01871 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515170018.0 | ||
| 264 | 0 | _c20090623 | |
| 008 | 200906s 0 0 eng d | ||
| 022 | _a1525-2191 | ||
| 024 | 7 |
_a10.2353/ajpath.2009.081026 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aOhishi, Masanobu | |
| 245 | 0 | 0 |
_aOsteoprotegerin abrogated cortical porosity and bone marrow fibrosis in a mouse model of constitutive activation of the PTH/PTHrP receptor. _h[electronic resource] |
| 260 |
_bThe American journal of pathology _cJun 2009 |
||
| 300 |
_a2160-71 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAlendronate _xpharmacology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiomechanical Phenomena |
| 650 | 0 | 4 |
_aBone Resorption _xmetabolism |
| 650 | 0 | 4 |
_aBone and Bones _xdrug effects |
| 650 | 0 | 4 |
_aDiphosphonates _xpharmacology |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyperparathyroidism _xmetabolism |
| 650 | 0 | 4 |
_aImidazoles _xpharmacology |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 |
_aOsteoclasts _xdrug effects |
| 650 | 0 | 4 |
_aOsteoprotegerin _xmetabolism |
| 650 | 0 | 4 | _aPorosity |
| 650 | 0 | 4 |
_aPrimary Myelofibrosis _xmetabolism |
| 650 | 0 | 4 |
_aReceptor, Parathyroid Hormone, Type 1 _xgenetics |
| 650 | 0 | 4 | _aTomography, X-Ray Computed |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aChiusaroli, Riccardo | |
| 700 | 1 | _aOminsky, Michael | |
| 700 | 1 | _aAsuncion, Frank | |
| 700 | 1 | _aThomas, Clare | |
| 700 | 1 | _aKhatri, Richa | |
| 700 | 1 | _aKostenuik, Paul | |
| 700 | 1 | _aSchipani, Ernestina | |
| 773 | 0 |
_tThe American journal of pathology _gvol. 174 _gno. 6 _gp. 2160-71 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2353/ajpath.2009.081026 _zAvailable from publisher's website |
| 999 |
_c18820653 _d18820653 |
||